BUSINESS COMBINATION (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended									12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	[1]	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Jun. 19, 2013
Business Acquisition, Transaction Costs												$ 7,088
Business Combination, Acquisition Related Costs												6,200
Business Combination Cost Of Acquired Entity Purchase Price													$ 29,800
Share Price													$ 1.22
Business Combination Deferred Tax Assets Established Gross	$ 9,600									$ 9,600
Business Combination Deferred Tax Liabilities Established Gross	3,900									3,900
Valuation allowance	5,700									5,700
Business Combination Purchase Price Allocation Deferred Tax Assets Net	0									0
Revenues, Total	$ 18,035	$ 19,972	$ 19,516	$ 18,799	$ 21,037		$ 17,387	$ 6,647	$ 10,899	$ 76,322	$ 55,970	30,082
Testosterone Gel NDA [Member]
Finite-Lived Intangible Asset, Useful Life										11 years
Selling, General and Administrative Expenses [Member]
Business Combination, Acquisition Related Costs												5,500
Interest Expense [Member]
Business Combination, Acquisition Related Costs												300
Other Expense [Member]
Business Combination, Acquisition Related Costs												400
BioSante Pharmaceuticals Inc [Member]
Business Acquisition, Percentage of Voting Interests Acquired													43.00%
Revenues, Total												$ 500
ANIP Acquisition Company [Member]
Business Acquisition, Percentage of Voting Interests Acquired													57.00%

[1] Net income from continuing operations, Basic income per share from continuing operations, and Diluted income per share from continuing operations for the fourth quarter of 2014 include the impact of an income tax benefit to reverse $16.7 million of the valuation allowance preiously recorded against our deferred tax assets.